|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu T, Ma P, Wu D, Shu Y and Gao W:
Functions and mechanisms of microRNA-31 in human cancers. Biomed
Pharmacother. 108:1162–1169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopcalic K, Petrovic N, Stanojkovic TP,
Stankovic V, Bukumiric Z, Roganovic J, Malisic E and Nikitovic M:
Association between miR-21/146a/155 level changes and acute
genitourinary radiotoxicity in prostate cancer patients: A pilot
study. Pathol Res Pract. 215:626–631. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Braga TV, Evangelista FCG, Gomes LC,
Araujo SSDS, Carvalho MDG and Sabino AP: Evaluation of MiR-15a and
MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
Biomed Pharmacother. 92:864–869. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrovic N: miR-21 might be involved in
breast cancer promotion and invasion rather than in initial events
of breast cancer development. Mol Diagn Ther. 20:97–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toiyama Y, Takahashi M, Hur K, Nagasaka T,
Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21
as a diagnostic and prognostic biomarker in colorectal cancer. J
Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuji T, Umeda Y, Nyuya A, Taniguchi F,
Kawai T, Yasui K, Toshima T, Yoshida K, Fujiwara T, Goel A and
Nagasaka T: Detection of circulating microRNAs with Ago2 complexes
to monitor the tumor dynamics of colorectal cancer patients during
chemotherapy. Int J Cancer. 144:2169–2180. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee RC and Ambros V: An extensive class of
small RNAs in caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pagliuca A, Valvo C, Fabrizi E, di Martino
S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L:
Analysis of the combined action of miR-143 and miR-145 on oncogenic
pathways in colorectal cancer cells reveals a coordinate program of
gene repression. Oncogene. 32:4806–4813. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nosho K, Igarashi H, Nojima M, Ito M,
Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, et
al: Association of microRNA-31 with BRAF mutation, colorectal
cancer survival and serrated pathway. Carcinogenesis. 35:776–783.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samowitz WS, Sweeney C, Herrick J,
Albertsen H, Levin TR, Murtaugh MA, Wolff RK and Slattery ML: Poor
survival associated with the BRAF V600E mutation in
microsatellite-stable colon cancers. Cancer Res. 65:6063–6069.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saridaki Z, Tzardi M, Sfakianaki M,
Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K,
Mavroudis D, Stathopoulos E, et al: BRAFV600E mutation analysis in
patients with metastatic colorectal cancer (mCRC) in daily clinical
practice: Correlations with clinical characteristics, and its
impact on patients' outcome. PLoS One. 8:e846042013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mori Y, Nagasaka T, Mishima H, Umeda Y,
Inada R, Kishimoto H, Goel A and Fujiwara T: The rare BRAF
VK600-601E mutation as a possible indicator of poor prognosis in
rectal carcinoma-a report of a case. BMC Med Genet. 16:12015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori Y, Nyuya A, Yasui K, Toshima T, Kawai
T, Taniguchi F, Kimura K, Inada R, Nishizaki M, Haraga J, et al:
Clinical outcomes of women with ovarian metastases of colorectal
cancer treated with oophorectomy with respect to their somatic
mutation profiles. Oncotarget. 9:16477–16488. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morikawa T, Inada R, Nagasaka T, Mori Y,
Kishimoto H, Kawai T, Umeda Y, Mishima H, Goel A and Fujiwara T:
BRAF V600E mutation is a predictive indicator of upfront
chemotherapy for stage IV colorectal cancer. Oncol Lett.
15:2195–2201. 2018.PubMed/NCBI
|
|
19
|
Edge S, Byrd D, Compton C, Fritz A, Greene
F and Trotti A: AJCC Cancer Staging Manual. https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%207th%20Ed%20Cancer%20Staging%20Manual.pdfJanuary
7–2013
|
|
20
|
Nagasaka T, Koi M, Kloor M, Gebert J,
Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, et
al: Mutations in both KRAS and BRAF may contribute to the
methylator phenotype in colon cancer. Gastroenterology.
134:1950–1960, 60.e1. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goel A, Nagasaka T, Hamelin R and Boland
CR: An optimized pentaplex PCR for detecting DNA mismatch
repair-deficient colorectal cancers. PLoS One. 5:e93932010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takehara Y, Nagasaka T, Nyuya A, Haruma T,
Haraga J, Mori Y, Nakamura K, Fujiwara T, Boland CR and Goel A:
Accuracy of four mononucleotide-repeat markers for the
identification of DNA mismatch-repair deficiency in solid tumors. J
Transl Med. 16:52018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagasaka T, Mori Y, Umeda Y and Fujiwara
T: Biomarker for colorectal cancer. Nihon Rinsho. 70:802–808.
2012.(In Japanese). PubMed/NCBI
|
|
26
|
Nikolaou S, Qiu S, Fiorentino F, Rasheed
S, Tekkis P and Kontovounisios C: Systematic review of blood
diagnostic markers in colorectal cancer. Tech Coloproctol.
22:481–498. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo
L and Lu SH: The oncogenetic role of microRNA-31 as a potential
biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond).
121:437–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Creighton CJ, Fountain MD, Yu Z, Nagaraja
AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM and
Anderson ML: Molecular profiling uncovers a p53-associated role for
microRNA-31 in inhibiting the proliferation of serous ovarian
carcinomas and other cancers. Cancer Res. 70:1906–1915. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Guo J, Li D, Xiao B, Miao Y,
Jiang Z and Zhuo H: Down-regulation of miR-31 expression in gastric
cancer tissues and its clinical significance. Med Oncol.
27:685–689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schee K, Boye K, Abrahamsen TW, Fodstad O
and Flatmark K: Clinical relevance of microRNA miR-21, miR-31,
miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC
Cancer. 12:5052012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cekaite L, Rantala JK, Bruun J, Guriby M,
Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe
RA and Skotheim RI: MiR-9, −31, and −182 deregulation promote
proliferation and tumor cell survival in colon cancer. Neoplasia.
14:868–879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang KH, Miller N, Kheirelseid EA,
Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ and Kerin MJ:
MicroRNA signature analysis in colorectal cancer: Identification of
expression profiles in stage II tumors associated with aggressive
disease. Int J Colorectal Dis. 26:1415–1422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cottonham CL, Kaneko S and Xu L: miR-21
and miR-31 converge on TIAM1 to regulate migration and invasion of
colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, −143 and −145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mansour MA, Hyodo T, Ito S, Kurita K,
Kokuryo T, Uehara K, Nagino M, Takahashi M, Hamaguchi M and Senga
T: SATB2 suppresses the progression of colorectal cancer cells via
inactivation of MEK5/ERK5 signaling. FEBS J. 282:1394–1405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eberhard J, Gaber A, Wangefjord S, Nodin
B, Uhlen M, Ericson Lindquist K and Jirström K: A cohort study of
the prognostic and treatment predictive value of SATB2 expression
in colorectal cancer. Br J Cancer. 106:931–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Magnusson K, de Wit M, Brennan DJ, Johnson
LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A,
et al: SATB2 in combination with cytokeratin 20 identifies over 95%
of all colorectal carcinomas. Am J Surg Pathol. 35:937–948. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J,
Zhang CY, Chen J and Zhang J: MicroRNA-31 activates the RAS pathway
and functions as an oncogenic MicroRNA in human colorectal cancer
by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol
Chem. 288:9508–9518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang MH, Yu J, Chen N, Wang XY, Liu XY,
Wang S and Ding YQ: Elevated microRNA-31 expression regulates
colorectal cancer progression by repressing its target gene SATB2.
PLoS One. 8:e853532013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng W, Ye Z, Cui R, Perry J,
Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H,
et al: MicroRNA-31 predicts the presence of lymph node metastases
and survival in patients with lung adenocarcinoma. Clin Cancer Res.
19:5423–5433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Manceau G, Imbeaud S, Thiebaut R, Liebaert
F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent
M, et al: Hsa-miR-31-3p expression is linked to progression-free
survival in patients with KRAS wild-type metastatic colorectal
cancer treated with anti-EGFR therapy. Clin Cancer Res.
20:3338–3347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mosakhani N, Lahti L, Borze I,
Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P,
Knuutila S and Sarhadi VK: MicroRNA profiling predicts survival in
anti-EGFR treated chemorefractory metastatic colorectal cancer
patients with wild-type KRAS and BRAF. Cancer Genet. 205:545–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mlcochova J, Faltejskova-Vychytilova P,
Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss
I, Vyzula R, et al: MicroRNA expression profiling identifies
miR-31-5p/3p as associated with time to progression in wild-type
RAS metastatic colorectal cancer treated with cetuximab.
Oncotarget. 6:38695–38704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Van Cutsem E, Huijberts S, Grothey A,
Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino
T, et al: Binimetinib, encorafenib, and cetuximab triplet therapy
for patients with BRAF V600E-mutant metastatic colorectal cancer:
Safety lead-in results from the phase III BEACON colorectal cancer
study. J Clin Oncol. 37:1460–1469. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wilmott JS, Long GV, Howle JR, Haydu LE,
Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA:
Selective BRAF inhibitors induce marked T-cell infiltration into
human metastatic melanoma. Clin Cancer Res. 18:1386–1394. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dummer R, Ascierto PA, Gogas HJ, Arance A,
Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer
R, et al: Overall survival in patients with BRAF-mutant melanoma
receiving encorafenib plus binimetinib versus vemurafenib or
encorafenib (COLUMBUS): A multicentre, open-label, randomised,
phase 3 trial. Lancet Oncol. 19:1315–1327. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Long GV, Hauschild A, Santinami M,
Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M,
Dutriaux C, Haydon A, et al: Adjuvant dabrafenib plus trametinib in
stage III BRAF-mutated melanoma. N Engl J Med. 377:1813–1823. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Planchard D, Besse B, Groen HJM, Souquet
PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, et
al: Dabrafenib plus trametinib in patients with previously treated
BRAF(V600E)-mutant metastatic non-small cell lung cancer: An
open-label, multicentre phase 2 trial. Lancet Oncol. 17:984–993.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hyman DM, Puzanov I, Subbiah V, Faris JE,
Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al:
Vemurafenib in multiple nonmelanoma cancers with BRAF V600
mutations. N Engl J Med. 373:726–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Corcoran RB, Ebi H, Turke AB, Coffee EM,
Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D,
Hung KE, et al: EGFR-mediated re-activation of MAPK signaling
contributes to insensitivity of BRAF mutant colorectal cancers to
RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hong DS, Morris VK, El Osta B, Sorokin AV,
Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, et al:
Phase IB study of vemurafenib in combination with irinotecan and
cetuximab in patients with metastatic colorectal cancer with
BRAFV600E mutation. Cancer Discov. 6:1352–1365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Corcoran RB, Andre T, Atreya CE, Schellens
JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S,
Middleton G, et al: Combined BRAF, EGFR, and MEK inhibition in
patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov.
8:428–443. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Connolly K, Brungs D, Szeto E and Epstein
RJ: Anticancer activity of combination targeted therapy using
cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant
metastatic colorectal carcinoma. Curr Oncol. 21:e151–e154. 2014.
View Article : Google Scholar : PubMed/NCBI
|
